899 related articles for article (PubMed ID: 24099035)
1. Dipeptidyl peptidase IV and its inhibitors: therapeutics for type 2 diabetes and what else?
Juillerat-Jeanneret L
J Med Chem; 2014 Mar; 57(6):2197-212. PubMed ID: 24099035
[TBL] [Abstract][Full Text] [Related]
2. Mechanism of action of inhibitors of dipeptidyl-peptidase-4 (DPP-4).
Thornberry NA; Gallwitz B
Best Pract Res Clin Endocrinol Metab; 2009 Aug; 23(4):479-86. PubMed ID: 19748065
[TBL] [Abstract][Full Text] [Related]
3. DPP-4 inhibitors in the treatment of type 2 diabetes.
Duez H; Cariou B; Staels B
Biochem Pharmacol; 2012 Apr; 83(7):823-32. PubMed ID: 22172989
[TBL] [Abstract][Full Text] [Related]
4. Cardiovascular pleiotropic actions of DPP-4 inhibitors: a step at the cutting edge in understanding their additional therapeutic potentials.
Balakumar P; Dhanaraj SA
Cell Signal; 2013 Sep; 25(9):1799-803. PubMed ID: 23707531
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of dipeptidyl peptidase IV (DPP-IV) by tryptophan containing dipeptides.
Nongonierma AB; Fitzgerald RJ
Food Funct; 2013 Dec; 4(12):1843-9. PubMed ID: 24193022
[TBL] [Abstract][Full Text] [Related]
6. The highly potent and selective dipeptidyl peptidase IV inhibitors bearing a thienopyrimidine scaffold effectively treat type 2 diabetes.
Deng J; Peng L; Zhang G; Lan X; Li C; Chen F; Zhou Y; Lin Z; Chen L; Dai R; Xu H; Yang L; Zhang X; Hu W
Eur J Med Chem; 2011 Jan; 46(1):71-6. PubMed ID: 21106276
[TBL] [Abstract][Full Text] [Related]
7. RBx-0597, a potent, selective and slow-binding inhibitor of dipeptidyl peptidase-IV for the treatment of type 2 diabetes.
Singh S; Roy S; Sethi S; Benjamin B; Sundaram S; Khanna V; Kandalkar SR; Pal C; Kant R; Patra AK; Rayasam G; Mittra S; Saini KS; Paliwal J; Chugh A; Ahmed S; Sattigeri J; Cliff I; Ray A; Bansal VS; Bhatnagar PK; Davis JA
Eur J Pharmacol; 2011 Feb; 652(1-3):157-63. PubMed ID: 20540938
[TBL] [Abstract][Full Text] [Related]
8. Novel DPP-4 inhibitors against diabetes.
Liu Y; Hu Y
Future Med Chem; 2014 May; 6(7):793-808. PubMed ID: 24941873
[TBL] [Abstract][Full Text] [Related]
9. Differential chemistry (structure), mechanism of action, and pharmacology of GLP-1 receptor agonists and DPP-4 inhibitors.
Neumiller JJ
J Am Pharm Assoc (2003); 2009; 49 Suppl 1():S16-29. PubMed ID: 19801361
[TBL] [Abstract][Full Text] [Related]
10. Recent progress of the development of dipeptidyl peptidase-4 inhibitors for the treatment of type 2 diabetes mellitus.
Li N; Wang LJ; Jiang B; Li XQ; Guo CL; Guo SJ; Shi DY
Eur J Med Chem; 2018 May; 151():145-157. PubMed ID: 29609120
[TBL] [Abstract][Full Text] [Related]
11. Inhibitor selectivity in the clinical application of dipeptidyl peptidase-4 inhibition.
Kirby M; Yu DM; O'Connor S; Gorrell MD
Clin Sci (Lond); 2009 Sep; 118(1):31-41. PubMed ID: 19780719
[TBL] [Abstract][Full Text] [Related]
12. DPP-4 inhibitors: a patent review (2012 - 2014).
Costante R; Stefanucci A; Carradori S; Novellino E; Mollica A
Expert Opin Ther Pat; 2015 Feb; 25(2):209-36. PubMed ID: 25482888
[TBL] [Abstract][Full Text] [Related]
13. Susceptibility of milk protein-derived peptides to dipeptidyl peptidase IV (DPP-IV) hydrolysis.
Nongonierma AB; FitzGerald RJ
Food Chem; 2014 Feb; 145():845-52. PubMed ID: 24128555
[TBL] [Abstract][Full Text] [Related]
14. Discovery of potent, selective, and orally bioavailable quinoline-based dipeptidyl peptidase IV inhibitors targeting Lys554.
Maezaki H; Banno Y; Miyamoto Y; Moritoh Y; Asakawa T; Kataoka O; Takeuchi K; Suzuki N; Ikedo K; Kosaka T; Sasaki M; Tsubotani S; Tani A; Funami M; Yamamoto Y; Tawada M; Aertgeerts K; Yano J; Oi S
Bioorg Med Chem; 2011 Aug; 19(15):4482-98. PubMed ID: 21741847
[TBL] [Abstract][Full Text] [Related]
15. Cardiovascular effects of dipeptidyl peptidase-4 inhibitors in patients with type 2 diabetes.
Koska J; Sands M; Burciu C; Reaven P
Diab Vasc Dis Res; 2015 May; 12(3):154-63. PubMed ID: 25852133
[TBL] [Abstract][Full Text] [Related]
16. An Update on Dipeptidyl Peptidase-IV Inhibiting Peptides.
Sivaraman SA; Sabareesh V
Curr Protein Pept Sci; 2024; 25(4):267-285. PubMed ID: 38173201
[TBL] [Abstract][Full Text] [Related]
17. Recent patents of dipeptidyl peptidase IV inhibitors.
Mendieta L; Tarrago T; Giralt E
Expert Opin Ther Pat; 2011 Nov; 21(11):1693-741. PubMed ID: 22017411
[TBL] [Abstract][Full Text] [Related]
18. Vascular protection with dipeptidyl peptidase-IV inhibitors in diabetes: experimental and clinical therapeutics.
Ahmed HA; May DW; Fagan SC; Segar L
Pharmacotherapy; 2015 Mar; 35(3):277-97. PubMed ID: 25754657
[TBL] [Abstract][Full Text] [Related]
19. The dipeptidyl peptidase-4 inhibitors in type 2 diabetes mellitus: cardiovascular safety.
Green JB
Postgrad Med; 2012 Jul; 124(4):54-61. PubMed ID: 22913894
[TBL] [Abstract][Full Text] [Related]
20. Finding a Potential Dipeptidyl Peptidase-4 (DPP-4) Inhibitor for Type-2 Diabetes Treatment Based on Molecular Docking, Pharmacophore Generation, and Molecular Dynamics Simulation.
Meduru H; Wang YT; Tsai JJ; Chen YC
Int J Mol Sci; 2016 Jun; 17(6):. PubMed ID: 27304951
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
